Sequential T and I with H101 via liver artery for advanced liver cancer.
Part of Cancer, Digestive system clinical trials.
This trial tests a new sequence of treatments for advanced liver cancer that hasn't been treated before. It uses a virus therapy (H101) delivered directly to the liver through a small tube, followed by two drugs (T and I) to shrink tumors and help your immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer that has spread to nearby lymph nodes or other parts of the body and hasn't been treated with liver-directed therapy or whole-body therapy.
- You are between 18 and 75 years old.
- You have at least one measurable liver tumor that is 1 cm or bigger on a scan.
- Your liver is working well enough (Child-Pugh score A or B).
- You can swallow pills.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This study tests a combination of a liver-directed treatment (TACE) with two immunotherapy drugs and bevacizumab for patients with liver cancer that cannot be surgically removed but has not spread outside the liver. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial is testing a new combination: a virus injected directly into the tumor, plus two drugs (tislelizumab and lenvatinib) that boost the immune system and block tumor blood supply. It is for people with advanced liver cancer who have not had similar treatments before.
This trial tests TTI-101, by itself and with other cancer medicines, for liver cancer that is advanced and cannot be removed by surgery. It aims to see whether the treatment can slow the cancer down and improve outcomes.
This trial tests combining a cancer-killing virus (H101) with a procedure that delivers chemo directly to the tumor (TACE) for people with advanced head and neck cancers that have not responded to at least two standard treatments. It aims to see if this combination can help shrink tumors and improve outcomes.
This Phase 1 study tests an oncolytic (tumor-attacking) virus given directly into liver arteries using a catheter. It’s for people with advanced liver cancer who have already tried standard treatments or can’t have them, aiming to assess safety and early anti-cancer activity.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.